Background

Previous demographic studies have revealed different CAD patterns among different population groups, with a more extensive and diffuse disease pattern among Egyptian/Arab patients particularly in a young age. These differences may be related to different risk factors distribution, socioeconomic factors or genetic aspects. DES performance is not adequately evaluated across different CAD patterns. The Xience V everolimus-eluting stent is a new-generation DES of proven safety and efficacy as shown in RCTs and multicenter registries.

Aim

The aim was to reproduce the safety and efficacy of the Xience V stent among Egyptian patients in a prospective multicenter all-comers registry.

Aim

The aim was to reproduce the safety and efficacy of the Xience V stent among Egyptian patients in a prospective multicenter all-comers registry.

Methods

A total of 426 consecutive patients were included in 20 centers; the exclusion criteria were very limited (primary PCI for STEMI, in-stent restenosis, using additional stents other than the study stent).

Primary endpoint

CMACE at 180 days: composite rate of all death, myocardial infarction (MI) and target vessel revascularization (TVR) at 180 days.

Secondary endpoints

MACE at 12 months: composite rate of cardiac death and MI at 6 and 12 months. Stent thrombosis as per ARC definition at 6 and 12 months.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Coronary stenting with MGuard: extended follow-up of first human trial
2. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
3. Treatment of STEMI with neither PCI nor thrombolysis
4. Definite stent thrombosis: a 2-center New Zealand registry

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree